

ondine



For Immediate Release

**Ondine Demonstrates High Efficacy of Photodisinfection Technology
Against Key Hospital Pathogen *Pseudomonas aeruginosa***

Vancouver, Canada – November 19, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) a medical technology company developing photodisinfection based products, today announced the conclusion of a preclinical program demonstrating high efficacy of its Photodisinfection technology against cultures and biofilms of *Pseudomonas aeruginosa*, one of the most dangerous hospital-acquired pathogens. This work provides important preclinical support for Ondine's photodisinfection programs for skin wounds, burn and outer ear infections.

“Our preclinical *Pseudomonas* program has evolved over the last two years, focusing on optimization of many photodisinfection parameters including dosing and formulation,” said Dr. Nicolas Loebel, Chief Technology Officer, Ondine Biopharma Corporation. “*Pseudomonas* is extremely difficult to kill and occurs throughout hospital environments as an opportunistic pathogen. Our photodisinfection system has demonstrated 100% eradication of *Pseudomonas aeruginosa* in planktonic (free-floating) cultures, and in excess of 99.9% kills in biofilms. The data from the preclinical research supports our belief that our photodisinfection technology could provide significant benefits over conventional antipseudomonal therapies such as topical antibiotics or micronized silver.

“*Pseudomonas* is a Gram-negative bacterium living in biofilm colonies surrounded by a viscous alginate matrix, a protective strategy that works so well that *Pseudomonas* has even been found living in hospital disinfectant solutions. The bacterium is notorious for its resistance to antibiotics. The case fatality rate in *Pseudomonas*-infected patients hospitalized with cancer, cystic fibrosis, burns and wounds is as high as 50%. Our photodisinfection technology has proven highly effective at disrupting *Pseudomonas* biofilms and rapidly killing the causative bacteria *in vitro*. The eradication process does not upregulate bacterial resistance factors because the process is rapid, the kill rates are high, and killing occurs through disruption of surface membranes rather than internal metabolic processes. After launching Periowave™, our ground-breaking photodisinfection treatment for adult periodontal disease, our new product development efforts are being focused into nasal MRSA decolonization, disinfection of skin wounds and burns and treatment of external ear infections. The combination of wide therapeutic window, absence of resistance and treatment speed implies a potentially new paradigm in the treatment of these complex infections.”

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broadspectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information please contact:

Carolyn Cross
President and
Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555
ccross@ondinebiopharma.com

Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269
cbessant@equicomgroup.com

Irma Gomez-Dib
Media & Investors Relations
FD International
(212) 850-5761
Irma.gomez.dib@fd.com

Nominated Adviser
Neil Johnson /
Ryan Gaffney
Canaccord Adams Ltd
+44(0)20 7050 6500